Pixee Medical has achieved FDA 510(k) clearance for its innovative augmented reality solution, Knee+ NexSight, which is specifically designed for total knee arthroplasty in U.S. ambulatory surgery centers (ASCs).

This solution offers robotic-like precision while avoiding the complexity and high costs typically associated with traditional robotic systems, thereby enhancing surgeons' intraoperative decision-making.

Built on the foundation of over 10,000 successful procedures, Knee+ NexSight addresses the needs of high-efficiency and cost-sensitive surgical environments.

Dr. Scott R. Nodzo noted that the system enables precise positioning of knee implants tailored to individual patient specifications, eliminating the necessity for costly preoperative imaging.

Additionally, Knee+ NexSight includes an optional connectivity module that facilitates secure data exchange with third-party web solutions, positioning surgical teams for future advancements in orthopedic care.

With the U.S. ASC market projected to exceed $75 billion by 2030, Knee+ NexSight emerges as a timely and sustainable solution that also minimizes environmental impact by reducing the need for physical disposables.

The system is compatible with all primary total knee implants and integrates seamlessly into various surgical settings, benefiting both outpatient centers and hospital practices.

Sébastien Henry, CEO of Pixee Medical, emphasized that Knee+ NexSight represents a new approach informed by U.S. surgeons and validated by proven results globally.

Pixee Medical has a strong track record of developing clinically proven augmented reality solutions for precise surgical procedures, demonstrating positive outcomes in over 20 countries.